Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (441-450 of 523) with videos related to

Pageof 53
Sort By:
Lancet (London, England)|March 18, 2020
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trialPhilip J Mease, Proton Rahman, Alice B Gottlieb, et al.
The British Journal of Dermatology|July 8, 2015
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trialsK A Papp, M A Menter, M Abe, et al.
Arthritis and Rheumatism|August 29, 2009
Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritisE H Giannini, N T Ilowite, D J Lovell, et al.
Journal of Drugs in Dermatology : JDD|January 22, 2015
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapiesAlice B Gottlieb, Robert E Kalb, Richard G Langley, et al.
The British Journal of Dermatology|June 14, 2005
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trialA B Gottlieb, C E M Griffiths, V C Ho, et al.
Dermatology and Therapy|May 30, 2025
Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal SymptomsJoseph F Merola, Philip J Mease, April W Armstrong, et al.
The Journal of Investigative Dermatology|December 22, 2004
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasisCatharine L Kauffman, Nancy Aria, Eiko Toichi, et al.
The Journal of Dermatological Treatment|December 20, 2012
Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severityMona L Martin, Kelly P McCarrier, Chiun-Fang Chiou, et al.
RMD Open|March 21, 2018
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritisDésirée van der Heijde, Atul Deodhar, Oliver FitzGerald, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 11, 2026
Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE StudyAlexis Ogdie, Joseph F Merola, Philip J Mease, et al.
Pageof 53

Showing results (441-450 of 523) with videos related to

Sort By:
Pageof 53
Lancet (London, England)|March 18, 2020
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trialPhilip J Mease, Proton Rahman, Alice B Gottlieb, et al.
The British Journal of Dermatology|July 8, 2015
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trialsK A Papp, M A Menter, M Abe, et al.
Arthritis and Rheumatism|August 29, 2009
Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritisE H Giannini, N T Ilowite, D J Lovell, et al.
Journal of Drugs in Dermatology : JDD|January 22, 2015
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapiesAlice B Gottlieb, Robert E Kalb, Richard G Langley, et al.
The British Journal of Dermatology|June 14, 2005
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trialA B Gottlieb, C E M Griffiths, V C Ho, et al.
Dermatology and Therapy|May 30, 2025
Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal SymptomsJoseph F Merola, Philip J Mease, April W Armstrong, et al.
The Journal of Investigative Dermatology|December 22, 2004
A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasisCatharine L Kauffman, Nancy Aria, Eiko Toichi, et al.
The Journal of Dermatological Treatment|December 20, 2012
Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severityMona L Martin, Kelly P McCarrier, Chiun-Fang Chiou, et al.
RMD Open|March 21, 2018
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritisDésirée van der Heijde, Atul Deodhar, Oliver FitzGerald, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 11, 2026
Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE StudyAlexis Ogdie, Joseph F Merola, Philip J Mease, et al.
Pageof 53